Skip to main content
Premium Trial:

Request an Annual Quote

Danaher to Acquire Aldevron for $9.6B

NEW YORK – Danaher announced on Thursday that it has entered into a definitive agreement to acquire Aldevron for approximately $9.6 billion.

Fargo, North Dakota-based Aldevron manufactures plasmid DNA, mRNA, and proteins for biotechnology and pharmaceutical customers in research, clinical, and commercial applications. The firm was founded in 1998, employs around 600 people, and is privately held.

Aldevron will operate as a standalone company and brand within Danaher's Life Sciences segment, which includes firms such as Beckman Coulter Life Sciences, Cytiva, Pall, Integrated DNA Technologies, Sciex, and several others.

The Washington, DC-based conglomerate plans to finance the acquisition using cash on hand and/or proceeds from the issuance of commercial paper.

"Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines," said Danaher CEO Rainer Blair in a statement. "This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more life-saving therapies and vaccines to market faster."

Shares of Danaher were up approximately 3 percent at $251.63 in Thursday morning trade on the New York Stock Exchange.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.